Osteosarcoma (OS) is the most common primary malignancy of bone. Here, we investigated a possible role of defective osteoblast differentiation in OS tumorigenesis. We found that basal levels of the early osteogenic marker alkaline phosphatase (ALP) activity were low in OS lines. Osteogenic regulators Runx2 and OSX, and the late marker osteopontin (OPN) expressed at low levels in most OS lines, indicating that most OS cells fail to undergo terminal differentiation. Furthermore, OS cells were refractory to osteogenic BMP-induced increases in ALP activity. Osteogenic BMPs were shown to upregulate early target genes, but not late osteogenic markers OPN and osteocalcin (OC). Furthermore, osteogenic BMPs failed to induce bone formation from human OS cells, rather effectively promoted OS tumor growth in an orthotopic OS model. Exogenous expression of early target genes enhanced BMP-stimulated OS tumor growth, whereas osteogenic BMP-promoted OS tumor growth was inhibited by exogenous Runx2 expression. These results suggest that alterations in osteoprogenitors may disrupt osteogenic differentiation pathway. Thus, identifying potential differentiation defects in OS tumors would allow us to reconstruct the tumorigenic events in osteoprogenitors and to develop rational differentiation therapies for clinical OS management.
Osteosarcoma (OS) is the most common primary malignancy of bone. Here, we investigated a possible role of defective osteoblast differentiation in OS tumorigenesis. We found that basal levels of the early osteogenic marker alkaline phosphatase (ALP) activity were low in OS lines. Osteogenic regulators Runx2 and OSX, and the late marker osteopontin (OPN) expressed at low levels in most OS lines, indicating that most OS cells fail to undergo terminal differentiation. Furthermore, OS cells were refractory to osteogenic BMP-induced increases in ALP activity. Osteogenic BMPs were shown to upregulate early target genes, but not late osteogenic markers OPN and osteocalcin (OC). Furthermore, osteogenic BMPs failed to induce bone formation from human OS cells, rather effectively promoted OS tumor growth in an orthotopic OS model. Exogenous expression of early target genes enhanced BMP-stimulated OS tumor growth, whereas osteogenic BMP-promoted OS tumor growth was inhibited by exogenous Runx2 expression. These results suggest that alterations in osteoprogenitors may disrupt osteogenic differentiation pathway. Thus, identifying potential differentiation defects in OS tumors would allow us to reconstruct the tumorigenic events in osteoprogenitors and to develop rational differentiation therapies for clinical OS management. Osteosarcoma (OS) is the most common nonhematolgic malignant tumor of bone in children and adults. 1- 3 The peak incidence of OS occurs in the teens.
1 OS tumors typically arise around the metaphysis of long bones and are often of high grade with poor prognosis. 4 OS is characterized by a high propensity for metastasis, mostly to the lungs, with 10-20% having detectable metastases at diagnosis. 5 Only B10% of OS patients achieve long-term disease-free interval. 6 The unifying histologic features of OS are the presence of malignant osteoid produced by neoplastic cells. 7 The molecular pathogenesis of OS is poorly understood. Certain genetic or acquired conditions increase the risk of OS. 8, 9 Patients with hereditary retinoblastoma have a high risk of OS 10 and OS may also arise in patients with Paget's disease of bone. 11 We have demonstrated that Wnt/b-catenin and S100A6 are frequently upregulated in human OS tumors. [12] [13] [14] Cytogenetic studies of OS have documented a variety of genetic alterations, resulting in inactivation of tumor suppressor genes and overexpression of oncogenes.
1,2,15,16 However, it is unclear how much these genetic changes contribute to OS development. 2, 3 Mesenchymal stem cells (MSCs) are adherent bone marrow stromal cells that can differentiate into osteogenic, chondrogenic, adipogenic, and myogenic lineages. [17] [18] [19] [20] [21] Osteoblastic differentiation of MSCs is an essential process of bone formation, [17] [18] [19] [20] and is tightly regulated. 20, 21 BMPs play an important role in osteoblast differentiation. 20, [22] [23] [24] We have analyzed the osteogenic potential of 14 human BMPs and found that BMP-2, 6, 9 are the most potent inducers of osteogenic differentiation both in vitro and in vivo. 19, 20, [24] [25] [26] We have further demonstrated that osteogenic BMPs regulate a distinct set of target genes, such as Id HLH factors and connective tissue growth factor (CTGF)/CCN2, during osteogenic differentiation. 19, 20, [27] [28] [29] Blockade of stem cell differentiation may lead to tumorigenesis. 3, 30 The stem cell features of tumor cells have been confirmed by a recent study, in which silencing of Ewing's sarcoma (EWS)-FLI-1 in Ewing's tumor cells leads to their recovery of MSC features, such as differentiating along adipogenic and osteogenic lineages, 31 whereas expression of the EWS/FLI-1 oncogene in murine MSCs results in EWSlike tumors. 32 Human OS tumors usually exhibit osteoblast-like features. 3, [33] [34] [35] [36] [37] [38] [39] We demonstrated that differentiation-promoting agents (eg, PPARg agonists and 9-cis retinoic acid) can induce osteoblast differentiation and inhibit OS cell proliferation. 3, 40 Here, we investigate whether the disruption of osteoblast differentiation plays a role in OS development. Using four commonly used OS lines and 12 primary OS lines derived from OS patients, we found that the early stages of osteogenic differentiation were preserved in most OS cells because these OS lines were responsive to osteogenic BMP-upregulated expression of the early target genes, but not late markers. Osteogenic BMPs failed to induce osteogenic differentiation of human OS cells in vivo, but effectively promoted OS tumor growth in an orthotopic model of human OS. Moreover, exogenous Id expression (especially Id2) was shown to enhance BMP-stimulated OS tumor growth, whereas osteogenic BMP-promoted OS tumor growth was inhibited by exogenous expression of Runx2, possibly by promoting osteogenic differentiation of the OS cells. Our findings suggest that genetic and/or molecular changes in osteoprogenitor cells may disrupt osteogenic differentiation pathway, subsequently leading to the OS development.
RESULTS

Early Osteogenic Marker ALP Activity is Low in Most
Human OS Tumor Cells Alkaline phosphatase (ALP) is a well-characterized early osteogenic marker that exhibits an elevated activity in committed preosteoblast cells and a decreased activity in the mature osteoblast cells. We measured the basal ALP activity in four human OS lines, MG63, U2OS, TE85, and SaOS2. As shown in Figure 1a , all OS lines displayed a higher basal ALP activity than that of mouse MSC line C3H10T1/2. The growth conditions (eg, different FCS concentrations) had a limited effect on the basal ALP activity of these OS lines. Among the four OS lines, MG63 exhibited the lowest basal ALP activity, whereas SaOS2 cells had the highest basal ALP activity. In fact, the basal ALP activities were approximately 7, 123, and 4129 times higher in U2OS, TE85, and SaOS2 cells than that in MG63 cells, respectively. The basal ALP activities in these OS lines were also confirmed by histochemical staining (Figure 1b) . On the basis of levels of basal ALP activity, we can conclude that SaOS2 is the most differentiated, followed by TE85, whereas MG63 is the least differentiated OS line. These findings are consistent with the in vitro cell proliferative activity and in vivo tumorigenic features of these lines. 41 We also analyzed the basal ALP activity in 12 primary OS lines derived from human OS tumors. Isolated normal human bone marrow stromal cells (hMSCs) were used as a control for uncommitted preosteoblasts, whereas the human osteoblast line hFOB1.19 was used as a control for committed osteoblasts. 42 As shown in Figure 1c , most primary OS lines exhibited low ALP activity, when compared with that of hFOB1.19 cells. Most primary OS lines also exhibited a much lower basal level of ALP activity than that of SaOS2, suggesting that majority of OS tumor cells may be less differentiated than SaOS2.
Low Expression of Osteogenic Regulators Runx2 and Osterix in most Human OS Cells
We next examined the endogenous expression levels of Runx2 and Osterix (OSX), both of which are important regulators of osteogenic differentiation, [17] [18] [19] [20] [21] 43 in OS lines. Osteoblast line hFOB1.19 and primary hMSC were used as controls. As shown in Figure 2a and b, most OS lines exhibited low levels of expression of Runx2 and OSX, whereas SaOS2 had the highest expression levels of both genes, consistent with the possibility that SaOS2 is more differentiated. These results indicate that osteogenic regulators Runx2 and/or OSX are expressed at low levels, suggesting that there may be differentiation defects upstream of Runx2 and/or OSX functions in most human OS cells.
Connective Tissue Growth Factor is Highly Expressed in Uncommitted Preosteoblast Progenitors and in most Human OS Cells
Connective tissue growth factor (a.k.a., CCN2), a member of the CCN family of modulator proteins, is a multifunctional growth factor for osteoblasts, chondrocytes, and vascular endothelial cells. 29 We previously demonstrated that CTGF is upregulated at the early stage of osteogenic differentiation. 29 We analyzed the basal CTGF expression in human OS cells. As shown in Figure 2c , almost all of the tested primary OS lines exhibited higher expression levels of CTGF than that of hFOB1.19, whereas MG63 (and to a lesser extent, U2OS) also had high basal level of CTGF expression. However, CTGF expression was low in SaOS2 and TE85. These results are consistent with other osteogenic parameters, suggesting that most OS lines may resemble early osteoprogenitors.
Expression Level of Late Osteogenic Marker
Osteopontin is Low in most Human OS Cells Osteopontin (OPN) is a well-characterized late marker of osteogenesis. 20, [24] [25] [26] As expected, mature osteoblast hFOB1.19 exhibited a high expression level of OPN, whereas hMSCs, representing a mix population of progenitors and osteogenic lineages at differentiation stages, had a modestly high expression level of OPN (Figure 2d ). However, all but one (ie, UCOS13) OS lines had significantly lower levels of OPN expression than that of hFOB1.19 cells (Figure 2d ).
These findings indicate that most OS cells fail to undergo terminal osteogenic differentiation.
Human OS Cells are Refractory to Osteogenic BMPInduced ALP Activity As shown in Figure 1 , most OS lines (except SaOS2, and to a lesser extent, TE85) exhibited low basal ALP activity. We sought to determine whether ALP activity could be induced upon osteogenic BMP stimulation. BMP2, BMP6, BMP7, and BMP9 are the most potent BMPs to induce osteogenic differ- Disrupted osteogenic differentiation in osteosarcoma X Luo et al entiation of MSCs. 19, 20, [24] [25] [26] We first analyzed the basal expression of the four BMPs in OS lines. As shown in Figure 3a , BMP7 was relatively highly expressed in the four OS lines tested, whereas BMP2 expression was the lowest in these OS lines. BMP6 and BMP9 expression levels were modest and readily detectable. We further examined the basal expression of Id1, Id2, and Id3 genes, which are important early targets of osteogenic BMP-induced osteogenic differentiation. 20, 27, 28 As shown in Figure 3b , expression of these Id genes was readily detected, although Id3 exhibited much higher expression levels than that of Id1 or Id2 in the tested OS lines.
We next analyzed the ALP activities in response to osteogenic BMP in OS cells. We previously demonstrated that BMP2 and BMP9 can effectively induce ALP activity in MSCs. 19, 20, [24] [25] [26] Our preliminary results indicated that most, if not all, of the TGFb/BMP types I and II receptors were expressed in the tested OS lines (data not shown). The four OS lines were stimulated with BMP2, BMP9, or GFP control, and their ALP activities were measured at days 5, 7, and 10. As shown in Figure 3c , neither BMP2 nor BMP9 induced any significant increases in ALP activities in the tested four OS lines at all time points. Notably, BMP2 induced a less than onefold increase in ALP activity in MG63 and U2OS cells at day 7, whereas BMP9 induced an approximately 50% increase in ALP activity in TE85 cells at day 10. These results suggest that these OS lines, except SaOS2 cells (and to a lesser Disrupted osteogenic differentiation in osteosarcoma X Luo et al extent, TE85) that exhibit high basal ALP activity, may harbor defects that lay upstream of the regulatory circuit of ALP activity at the early stages of osteogenic differentiation.
Osteogenic BMPs Upregulate the Expression of Early
Target Genes Id1, Id2, and Id3 in OS Cells, Whereas the Expression of Late Markers OPN and Osteocalcin is not Affected by Osteogenic BMPs We stimulated the four OS lines and two primary OS lines with BMP2, BMP6, BMP9, or GFP, and analyzed the expression of Id1, Id2, and Id3 by using qPCR. As illustrated in Figure 4a , Id1 expression was readily induced (2-to 9-fold) by all three BMPs in the four OS lines, whereas the induction of Id2 and Id3 expression was apparent but exhibited significant variations among the OS lines and/or three BMPs. Among the three BMPs, BMP2 was shown to be an effective inducer of the Id genes in three of the four OS lines (ie, except MG63). These results may reflect the fact that the basal expression of BMP2 is lower in OS lines than that of BMP6 and BMP9 (Figure 3a ). Of the three Id genes, Id3 was shown to be in general the least inducible (Figure 4a ), which may be due to the high basal level of Id3 expression (Figure 3b) . Similar results about BMP2 and BMP9-induced Id gene expression were obtained in two primary OS lines, UCOS1 and UCOS12 (Figure 4b ). These findings suggest that the early stages of osteogenic differentiation may be preserved. We also found that the inhibitory Smad6 and Smad7, which are considered as feedback inhibitors of BMP signaling, were significantly upregulated in these OS cells upon BMP stimulation, indicating that the early stage of the BMP signaling pathway may remain intact in these OS cells (data not shown).
We further analyzed the BMP-regulated expression of the late osteogenic markers OPN and osteocalcin (OC) in the OS cells. We previously demonstrated that BMP2, BMP6, and BMP9 can effectively upregulate OPN and OC expression in MSCs. 19, 20, [24] [25] [26] As shown in Figure 4c , BMP2, BMP6, and BMP9 failed to induce any significant increases in OC expression in MG63, U2OS, and SaOS2 cells, although there was a small (o2.5-fold) but consistent induction of OPN expression in TE85 cells. Most OS lines, however, did not exhibit any significant increases in OPN expression upon osteogenic BMP stimulation (although there was a less than twofold increase in MG63 cells; Figure 4c ). These findings, together with the results shown in Figure 3c , strongly suggest that these OS lines may contain impairments in the osteogenic pathway, preventing the OS cells from undergoing terminal differentiation.
Osteogenic BMPs Fail to Induce Osteogenic Differentiation of Human OS Cells In Vivo, but Promote Tumor Growth in an Orthotopic Model of Human OS We next sought to determine the effect of osteogenic BMPs on osteogenic differentiation vs OS tumor growth in an orthotopic model of human OS tumors. 41 We used MG63 line and another frequently used OS line 143B for the in vivo studies, as TE85, U2OS, and SaOS2 did not readily form tumors in xenograft models. 41 We first analyzed whether BMP2 or BMP9-tranduced OS cells were able to induce bone formation in vivo. We infected MG63 and normal MSC line C3H10T1/2 cells with AdBMP2, AdBMP9, or AdGFP and implanted the transduced cells subcutaneously in athymic mice. At 6 weeks after implantation, animals were killed, and the retrieved masses were subjected to histologic evaluation. It should be noted that GFP-transduced C3H10T1/2 and MG63 cells did not form any detectable masses. As shown in Figure 5a , both BMP2 and BMP9-transduced C3H10T1/2 cells induced robust bone formation (panels i and ii), consistent with our early studies. 20, 26, 44 However, BMP2 or BMP9-transduced MG63 cells did not exhibited any bone formation (Figure 5a , panels iii and iv). Similar results were obtained when we conducted subcutaneous injection with BMP2-or BMP9-transduced other human OS lines (Supplementary Figure 1a) . These results further substantiate our in vitro findings, suggesting that most OS cells may harbor differentiation defects and are refractory to osteogenic BMP-induced osteogenic differentiation.
We next examined the effect of osteogenic BMPs on tumor growth. Transduced MG63-Luc cells with AdBMP9 or AdGFP were injected into proximal tibiae of athymic mice. The tumor growth was monitored by Xenogen bioluminescence imaging. As shown in Figure 5b , BMP9-promoted tumor growth of MG63 cells in a time-dependent manner (panel i). MG63 cells stimulated with GFP control did not form significant tumors up to 10 weeks after injection, whereas BMP9 was shown to effectively promote tumor growth (Figure 5b , panels ii vs iii). Similar experiments were carried out by using another commonly used human OS line 143B, which is derived from k-Ras transformed TE85 cells and is one of the most tumorigenic OS lines. 41 Both BMP2 and BMP9 were shown to effectively enhance the growth of the xenograft tumors formed by transduced 143B-Luc cells (Figure 5c, panel i) . The gross appearance of the xenograft tumors is consistent with the bioluminescence imaging results, although Xenogen signal in BMP9-treated group might have underestimated tumor sizes due to the rapid tumor growth and necrosis (Figure 5c , panels ii and iii vs i). The tumor-promoting effect of osteogenic BMPs on OS cells was reproducibly observed when BMP6 or BMP7 were used, or carried out in other OS lines (data not shown). Thus, these in vivo results are consistent with the possibility that OS cells may harbor differentiation defects at the early stages of osteogenesis, rendering the defective osteoprogenitors high proliferative potential. As a result, osteogenic stimuli (such as BMPs) would further promote the proliferation of these OS cells.
Exogenous Id Expression Enhances BMP-Stimulated OS Tumor Growth
It is conceivable that, if the defects are downstream of Id gene regulation, overexpression of Id genes may potentiate BMPs exert no significant effect on the expression of late osteogenic marker osteocalcin and osteopontin in human OS lines. Subconfluent OS lines were infected with AdBMP2, AdBMP6, AdBMP9, and AdGFP. At 7 days after infection, total RNA was isolated from the infected cells and subjected to reverse transcription and qPCR analysis using primers specific for human osteocalcin and osteopontin (listed in Supplementary Table 1) . Each assay condition was done in triplicate. Fold of changes was calculated by dividing the relative expression level from BMP-treated samples with that of GFP-treated samples. The dotted lines indicate that the fold of change is 1.0 (ie, BMP-induced expression is equal to that of GFP control-treated cells). See text for detail.
Disrupted osteogenic differentiation in osteosarcoma X Luo et al BMP-promoted tumor growth. On the basis of our in vitro studies shown in Figure 4a and b, we anticipated that exogenous Id expression could enhance BMPs' effect on OS tumor growth. To test this possibility, we established MG63 sublines that stably express Id1, Id2, Id3, or vector control. Exogenous expression of Id genes in these pooled stable lines were confirmed (Supplementary Figure 1b) . These Id stable lines and vector control line were infected with AdBMP9 or AdGFP and subsequently subjected to intratibial injection as described in Figure 5b . As shown in Figure 6a , Id2 overexpression significantly enhanced BMP9-promoted tumor growth at all time points except at week 10, the decrease in signal at week 10 is likely related to tumor necrosis. Likewise, Id3 expression was also shown to modestly enhance BMP9-promoted tumor growth (Figure 6a , panel i, compared with Figure 5b ). Overexpression of Id1 did not exert any significant effect on BMP9-promoted tumor growth, although Id1 expression was shown to slightly enhance tumor growth beyond 8 weeks post-injection. Interestingly, Xenogen signals were in general higher during the first week and 
Osteogenic BMP-Promoted OS Tumor Growth is Inhibited by Exogenous Expression of Runx2
We further examined whether overexpression of Runx2 would exert any effect on BMP-promoted OS tumor growth. MG63-Luc cells transduced with AdBMP9, AdGFP, and/or AdRunx2 were injected intratibially as described in Figure 5b . Exogenous expression of Runx2 was shown to inhibit BMP9-stimulated tumor growth at all time points (Figure 6b , panel i).
Representative Xenogen images are shown in Figure 6b, Figure 2) , although the detailed mechanism requires further investigations. These in vivo and in vitro findings suggest that some of the OS lines may harbor differentiation defects upstream Runx2 functionality and may become more differentiated when induced with Runx2.
Osteogenic BMPs Promote Cell Proliferation in Early Progenitors and in OS Cells
Lastly, we examined whether osteogenic BMPs exert any effects on cell proliferation of MSCs and OS cells. C3H10T1/2 cells were infected with AdGFP or AdBMP9 for 24, 72, and 120 h post-infection, and subjected to flow cytometry. As shown in Figure 7a , AdBMP9-infected C3H10T1/2 cells exhibited much higher percentages of cells in S phase than that of control (Po0.01), consistent with the notion that On the basis of these findings, we propose a model that depicts the relationship between osteogenic differentiation and OS tumorigenesis (Figure 7c ). Osteogenic differentiation of MSCs is a multistep process that requires a balanced regulation of proliferation and differentiation of osteoprogenitors [17] [18] [19] [20] 43 (Figure 7c, panel i) . Disruptions of osteogenic differentiation may lead to the development of OS. 3 It is conceivable that osteoprogenitor cells harboring defects at the early stage of osteogenic pathway may lead to the development of less differentiated and more aggressive OS tumors, whereas OS tumors may be more differentiated if they are caused by defects occurring at later stages of osteogenic pathway (Figure 7c, panel ii) . Some of the OS lines may harbor differentiation defects upstream Runx2 functionality and may become more differentiated when induced with Runx2 or other differentiation agents. 3, 40 This model is supported by the following facts. First, OS cells exhibit the characteristics of undifferentiated osteoblasts. 3, [33] [34] [35] [36] [37] [38] [39] Second, we demonstrated that differentiationpromoting agents (eg, PPARg agonists and 9-cis retinoic acid) can induce OS differentiation and inhibit OS proliferation. 3, 40 Third, a recent study that showed Runx2 and p27
KIP1 -mediated osteoblast terminal differentiation is disrupted in OS. 39 Fourth, in EWS, the second most common malignant pediatric bone tumor caused by oncogenes EWS/ FLI-1 or EWS/ETS, EWS/ETS fusion proteins block differentiation along osteogenic and adipogenic lineages of MSCs. 45 Fifth, EWS-FLI1-silenced Ewing's cell lines can differentiate along adipogenic lineage, or osteogenic lineage when stimulated with appropriate differentiation cocktails, suggesting that the inhibition of EWS-FLI1 may allow Ewing's cells to recover the phenotype of their MSC progenitors. 31 Lastly, expression of EWS/FLI-1 oncogene in murine primary MSCs results in EWS/FLI-1-dependent, Ewing's sarcoma-like tumors. 32 Numerous cytogenetic studies of OS have described a variety of genetic alterations resulting in inactivation of tumor suppressor genes and overexpression of oncogenes. 1, 2, 15, 16 In particular, many OS tumors harbor genetic lesions that inactivate Rb and/or p53 pathways.
1,15,46 Conversely, several oncogenes, such as FOS, MYC, MET, SAS, GLI, MDM2, CDK4, and ERBB2, are reportedly overexpressed or activated in some OS.
1, 16 We and others have reported that Wnt signaling pathway is also deregulated in OS tumors. 12, 47, 48 Currently, it is unclear how much these genetic and molecular changes contribute to the development of human OS. 2, 3 However, it is conceivable that some of the genetic and/or molecular changes in osteoprogenitors may disrupt osteogenic differentiation pathway, subsequently leading to the development of human OS tumors.
It has been reported that Rb functions as a direct transcriptional co-activator promoting osteoblast differentiation. 49 Loss of pRb has been shown to block late osteoblast differentiation, and pRb physically interacts with Runx2, resulting in synergistic transactivation of an osteoblastspecific reporter. 49 It has been reported that osteoblast differentiation is regulated by MDM2-p53 signaling pathway. 50 Osteoprogenitor cells deleted for MDM2 have elevated p53 activity, reduced level of Runx2 and decreased osteogenic differentiation. Conversely, the p53-null osteoprogenitor cells have increased Runx2 expression, increased osteoblast maturation, and yet increased tumorigenic potential as mice specifically deleted p53 in osteoblasts develop OS tumors. 50 Future investigations should be directed to identify the genetic and molecular alterations that may disrupt osteogenic differentiation.
In summary, our results suggest that in most OS cells the early stages of osteogenic differentiation may be preserved, but these OS lines may have defects in osteogenic terminal differentiation. As a result, osteogenic stimuli (such as BMPs) were unable to induce bone formation from OS cells, and rather promoted OS tumor growth because the OS cells were locked in the early proliferative phase of osteogenic pathway. We have shown that differentiation agents, such as PPARg agonists and retinoid acid receptor ligands, are able to inhibit OS proliferation and induce osteogenic differentiation. 3, 40 Interestingly, BMPs and/or their receptors are readily expressed in OS cells. [51] [52] [53] [54] [55] [56] Thus, understanding the genetic Recombinant Adenoviruses Expressing GFP, BMPs, and Runx2 Adenoviruses expressing BMP2, BMP6, BMP9, and Runx2 were generated using the AdEasy technology as described. [25] [26] [27] 57, 58 An analogous adenovirus expressing only GFP (AdGFP) was used as a control. 57, 59, 60 ALP Assays Alkaline phosphatase activity was assessed by colorimetric assay and/or histochemical staining assay as described.
25-29,61
Establishment of OS Lines Stably Expressing Luciferase MG63-Luc and 143B-Luc were generated by using a retroviral vector expressing firefly luciferase. Luciferase activity of the pooled stable cells was assessed by using Promega's Luciferase Assay system (see Supplementary Methods).
Establishment of Id-Expressing Stable Lines
Retroviral viruses expressing mouse Id1, Id2, and Id3 were used to infect MG63-Luc cells under hygromycin selection. 62 The resultant stable pools were designated as MG63-Id1, MG63-Id2, MG-Id3, and control MG63-RV. Overexpression of Id genes was verified by quantitative real-time PCR (qPCR; see Supplementary Methods).
RNA Isolation and Quantitative Real-Time PCR Analysis
Total RNA was isolated using Trizol Reagents (Invitrogen). qPCR was carried out as described. 28, 29, 61 qPCR primers (Supplementary Table 1) were 18-mers, designed by using the Primer3 program to amplify the gene of interest (approximately 120 bp). All samples were normalized by the expression level of GAPDH (see Supplementary Methods).
Subcutaneous Implantation of MSCs and OS Cells C3H10T1/2 and MG63 cells infected with AdBMP2, AdBMP9, or AdGFP for 16 h were collected for subcutaneous injection (5 Â 10 6 cells per injection, 4 injections per group) into the flanks of athymic mice. At 6 weeks, animals were killed and the implantation sites were retrieved for histologic evaluation (see Supplementary Methods).
Intratibial Tumor Injection MG63-Luc and 143B-Luc cells were infected with adenoviruses (BMPs, GFP, and/or Runx2). Cells were harvested, and resuspended in PBS to a final density of 2 Â 10 7 cells per ml. Cells (1 Â 10 6 ) in 50 ml of PBS were injected into the proximal tibiae of athymic mice as described. 41 Animals injected with MG63-Luc were killed after 10 weeks, whereas 143B-Luc injected animals were killed after 6 weeks (see Supplementary Methods).
Xenogen Bioluminescence Imaging
Animal were anesthetized with isoflurane attached to a nosecone mask within Xenogen IVIS 200 imaging system. For bioluminescence imaging, animals were injected (i.p.) with D-Luciferin sodium salt (Gold BioTechnology) at 100 mg/kg in 0.1 ml sterile saline. The pseudoimages were obtained by superimposing the emitted light over the gray-scale photographs of the animal. Quantitative analysis was done with Xenogen's Living Image V2.50.1 software (see Supplementary Methods).
Histological Evaluation
Retrieved tissues were fixed in 10% formalin overnight (decalcified if necessary) and embedded in paraffin. Serial sections of the embedded specimens were stained with hematoxylin and eosin, and other staining. 63 Cell-Cycle Analysis Cells were infected with GFP or BMP9 adenovirus. At indicated time points, cells were collected, fixed, and then incubated with the propidium iodide (PI)/RNase staining buffer (BD Biosciences Pharmingen), followed by flow cytometry assay (see Supplementary Methods).
